Following the transaction, the director now directly owns 6,296 shares in the company, valued at $684,564.08. Parallel Advisors LLC raised its holdings in shares of Quest Diagnostics by 16.1% during the 1st quarter. It fall, as 38 investors sold Quest Diagnostics Inc shares while 200 reduced holdings. Parallel Advisors LLC now owns 1,279 shares of the medical research company's stock valued at $137,000 after acquiring an additional 177 shares during the period. Financial Architects Inc now owns 1,666 shares of the medical research company's stock valued at $185,000 after acquiring an additional 88 shares during the period. Zacks Investment Research raised shares of Quest Diagnostics from a "hold" rating to a "buy" rating and set a $121.00 price objective for the company in a research note on Wednesday, August 2nd.
Technical traders may be looking at recent indicator levels on shares of Quest Diagnostics Inc (DGX). 1,026,597 shares of the company traded hands. The stock has a market capitalization of $13.93 billion, a PE ratio of 20.58 and a beta of 0.69.
The company's P/E ratio is 19.32 and market cap is 13.07B. The firm's 50-day moving average is $106.58 and its 200 day moving average is $105.42.
News stories about Quest Diagnostics (NYSE:DGX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The medical research company reported $1.55 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.42 by $0.13. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. After $1.55 actual EPS reported by Quest Diagnostics Inc for the previous quarter, Wall Street now forecasts -7.74% negative EPS growth. The business's revenue was up 1.9% on a year-over-year basis. On average, equities analysts expect that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. This represents a $1.80 annualized dividend and a dividend yield of 1.76%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics has $12300 highest and $68 lowest target. (FNF) - averaging the work of different analysts - reveals a mean PT of $50.6/share. The stock of Quest Diagnostics Inc (NYSE:DGX) has "Buy" rating given on Monday, November 14 by UBS.
Among 19 analysts covering Quest Diagnostics (NYSE:DGX), 8 have Buy rating, 2 Sell and 9 Hold. As per Thursday, July 27, the company rating was maintained by Deutsche Bank. They noted that the move was a valuation call. The consensus target price is $74.13 with 1 firm rating the stock a strong buy, 2 firms rating the stock a buy, 17 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 0 firms rating the stock a sell. Canaccord Genuity has "Buy" rating and $11800 target.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another website, it was stolen and republished in violation of US & global copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/09/24/laurion-capital-management-lp-purchases-36800-shares-of-quest-diagnostics-incorporated-dgx.html. $102.65's average target is 5.08% above currents $97.69 stock price. Following the sale, the director now directly owns 6,000 shares in the company, valued at $639,960. Aberdeen Asset Management PLC UK owned about 0.15% of Quest Diagnostics worth $22,755,000 as of its most recent filing with the Securities and Exchange Commission.
We can also take a look at the relative price change value for the stock. The institutional investor owned 204,699 shares of the medical research company's stock after selling 24,738 shares during the quarter. The disclosure for this sale can be found here. Insiders have sold a total of 161,996 shares of company stock valued at $17,517,207 over the last ninety days. Following multiple time frames using moving averages can help investors figure out where the stock has been and help determine where it may be possibly going.
Quest Diagnostics Incorporated, launched on September 20, 1996, is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions.